Slade Pharmacy showcases record research achievements at 2025 AdPha and COSA conferences

Slade Team / 26 Nov, 2025

Slade Pharmacy (Slade) has proudly presented a record number of abstracts at the 2025 Advanced Pharmacy Australia (AdPha) Medicines Management Conference and the COSA–IPOS Annual Scientific Meeting.

The achievement reflects Slade’s strengths in research and governance, demonstrating how evidence-based practice, strong clinical systems, and continuous improvement form the backbone of our service to hospital partners across Australia.

Across both conferences, Slade pharmacists showcased work that directly contributes to safer, more consistent and patient-centred pharmacy services.

From enhancing medication safety in cancer care and developing advanced digital tools, to improving antimicrobial reporting and strengthening transitions of care, each abstract highlights Slade’s commitment to delivering best-practice pharmacy services underpinned by robust governance.

Patient focused, governance-led innovationPatient focused, governance-led innovation

These initiatives are led and supported by our national Quality and Medication Safety Unit (QMSU), which provides the frameworks, quality assurance programs, and education that enable our teams to deliver safe and high-quality care across metropolitan, regional, and private hospital settings.

Head of QMSU, Claire Fitzgerald, said the contributions reflect Slade’s long-standing commitment to quality and the future of hospital pharmacy.

“Each abstract is a practical example of how strong governance and thoughtful innovation improve the patient experience,” said Claire.

“This work not only informs our national frameworks but directly enhances the services we deliver to our hospital partners every day.”

Celebrating 60 years of pharmacy excellence

As Slade celebrates six decades of excellence, these research achievements further demonstrate the legacy established in 1965: a commitment to innovation, integrity, and exceptional patient care.

CEO for Pharmacy and Compounding, Russell Hill said the milestone reinforces Slade’s role as a trusted partner in patient safety and medicine management.

“For 60 years, Slade has invested in clinical excellence and strong governance,” said Russell.

“These research contributions reflect the depth of expertise across our teams and our ongoing commitment to delivering the safest, most effective pharmacy services for hospitals nationwide.”

Advancing patient care through evidence and practice Advancing patient care through evidence and practice

The presentations delivered at AdPha and COSA showcase Slade’s leadership in:

  • Medication safety across oncology, critical care and high-risk therapies
  • Digital and workflow innovations that reduce clinical risk
  • Antimicrobial stewardship and reporting improvements
  • Enhanced patient experience and transitions of care
  • Strengthened governance systems supporting clinicians across hospital settings.

This work continues to shape the service models applied at Slade’s hospital sites, reinforcing our commitment to safe, evidence-based practice across Australia.

Explore our full collection of 2025 conference abstracts below.

View all News & Updates

Search

Contact us
Order Your Medication